Rupesh Agrawal1,2,3, Dinesh Visva Gunasekeran1,3,4, Aniruddha Agarwal5, Ester Carreño6, Kanika Aggarwal5, Bhaskar Gupta7, Dhananjay Raje8, Somasheila I Murthy9, Mark Westcott1, Soon Phaik Chee2,10, Peter McCluskey11, Ho Su Ling3, Stephen Teoh3, Luca Cimino12, Jyotirmay Biswas13, Shishir Narain14, Manisha Agarwal15, Padmamalini Mahendradas16, Moncef Khairallah17, Nicholas Jones18, Ilknur Tugal-Tutkun19, Kalpana Babu20, Soumayava Basu21, Richard Lee6, Hassan Al-Dhibi22, Bahram Bodaghi23, Alessandro Invernizzi24, Debra A Goldstein25, Carl P Herbort26, Talin Barisani-Asenbauer27, Julio J González-López28, Sofia Androudi29, Reema Bansal5, Bruttendu Moharana5, Sarakshi Mahajan5, Simona Esposti1, Anastasia Tasiopoulou1, Sengal Nadarajah1, Mamta Agarwal13, Sharanya Abraham13, Ruchi Vala16, Joanne Lord30, Ramandeep Singh5, Aman Sharma31, Kusum Sharma32, Manfred Zierhut33, Onn Min Kon34, John Kempen35,36, Emmett T Cunningham37,38,39, Andres Rousselot40, Quan Dong Nguyen39, Carlos Pavesio1, Vishali Gupta5. 1. Department of Medical retina and uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, UK. 2. Department of Ophthalmology, Singapore Eye Research Institute, Singapore. 3. National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore. 4. School of Medicine, National University of Singapore, Singapore. 5. Advanced Eye Centre, Department of Ophthalmology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. 6. Department of Ophthalmology, Bristol Eye Hospital, Bristol, UK. 7. Department of Ophthalmology, Royal Berkshire Hospital, NHS Foundation Trust, Reading, UK. 8. MDS Bioanalytics, India. 9. Dept of Statistics, Tej Kohli Cornea Institute, LV Prasad Eye Institute, Nagpur, India. 10. Department of Ophthalmology, Singapore National Eye Centre, Singapore. 11. Department of Clinical Ophthalmology & Eye Health, Central Clinical School, Save Sight Institute, The University of Sydney, Sydney, Australia. 12. Ocular Immunology Unit, Department of Ophthalmology, Arcispedale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. 13. Department of Ophthalmology, Sankara Nethralaya, Chennai, India. 14. Department of Ophthalmology, Shroff Eye Centre, New Delhi, India. 15. Department of Ophthalmology, Dr Shroff's Charity Eye Hospital Daryaganj, New Delhi, India. 16. Department of Ophthalmology, Narayana Nethralaya, Bangalore, India. 17. Department of Ophthalmology, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia. 18. Department of Ophthalmology, University of Manchester, Manchester, UK. 19. Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 20. Department of Ophthalmology, Prabha Eye Clinic & Research centre, Vittala International Institute of Ophthalmology, Bangalore, India. 21. Department of Ophthalmology, LV Prasad Eye Institute, Bhubaneswar, India. 22. Department of Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia. 23. Department of Ophthalmology, DHU SightRestore, University of Pierre and Marie Curie, Paris, France. 24. Eye Clinic, Department of Biomedical and Clinical Science "L. Sacco", Luigi Sacco Hospital, University of Milan, Milan, Italy. 25. Department of Ophthalmology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. 26. Centre for Ophthalmic Specialised Care & University of Lausanne, Laussane, Switzerland. 27. Laura Bassi Centre of Expertise Ocuvac, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria. 28. Department of Ophthalmology, Ramón y Cajal University Hospital,Madrid, Spain. 29. Department of Ophthalmology, University of Thessaly, Thessaly, Greece. 30. Southampton Health Technology Assessments Centre (SHTAC), Southampton, United Kingdom. 31. Department of Rheumatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. 32. Department of Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. 33. Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany. 34. Chest and Allergy Clinic, St Mary's Hospital, Imperial College Healthcare NHS Trust, London. 35. Department of Ophthalmology, Massachusetts Eye and Ear, Boston, USA. 36. The Discovery Eye Center, MyungSung Christian Medical Center and MyungSung Medical School, Addis Ababa, Ethiopia. 37. The Department of Ophthalmology, California Pacific Medical Center, San Francisco, California, USA. 38. The Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Stanford, California, USA. 39. The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, California, USA. 40. Department of Ophthalmology, Universidad del Salvador of Buenos Aires, Buenos Aires, Argentina.
Abstract
Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU). Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed. Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06). Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.
Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU). Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed. Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06). Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.
Authors: Onn Min Kon; Nicholas Beare; David Connell; Erika Damato; Thomas Gorsuch; Guy Hagan; Felicity Perrin; Harry Petrushkin; Jessica Potter; Charanjit Sethi; Miles Stanford Journal: BMJ Open Respir Res Date: 2022-03